Saccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis

Página do item simplificado
dc.creatorRafael Wesley Bastos
dc.creatorSílvia Helena Sousa Pietra Pedroso
dc.creatorAngélica Thomaz Vieira
dc.creatorLuciana Mara Costa Moreira
dc.creatorC. S. França
dc.creatorChristiane Teixeira Cartelle
dc.creatorRosa Maria Esteves Arantes
dc.creatorSimone de Vasconcelos Generoso
dc.creatorValbert Nascimento Cardoso
dc.creatorMaria José Neves
dc.creatorJacques Robert Nicoli
dc.creatorFlaviano dos Santos Martins
dc.date.accessioned2022-03-15T21:48:53Z
dc.date.accessioned2025-09-09T00:45:26Z
dc.date.available2022-03-15T21:48:53Z
dc.date.issued2016
dc.identifier.doihttps://doi.org/10.3920/BM2015.0190
dc.identifier.issn1876-2891
dc.identifier.urihttps://hdl.handle.net/1843/40135
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofBeneficial Microbes
dc.rightsAcesso Restrito
dc.subjectProbióticos
dc.subjectSaccharomyces cerevisiae
dc.subjectTratamento farmacológico
dc.subjectMucosite
dc.subjectEstresse oxidativo
dc.subject.otherProbiotic
dc.subject.otherSaccharomyces cerevisiae UFMG A-905
dc.subject.otherChemotherapy
dc.subject.otherMucositis
dc.subject.otherOxidative stress
dc.titleSaccharomyces cerevisiae UFMG A-905 treatment reduces intestinal damage in a murine model of irinotecan-induced mucositis
dc.typeArtigo de periódico
local.citation.epage557
local.citation.issue4
local.citation.spage549
local.citation.volume7
local.description.resumoIndigenous microbiota plays a crucial role in the development of several intestinal diseases, including mucositis. Gastrointestinal mucositis is a major and serious side effect of cancer therapy, and there is no effective therapy for this clinical condition. However, some probiotics have been shown to attenuate such conditions. To evaluate the effects of Saccharomyces cerevisiae UFMG A-905 (Sc-905), a potential probiotic yeast, we investigated whether pre- or post-treatment with viable or inactivated Sc-905 could prevent weight loss and intestinal lesions, and maintain integrity of the mucosal barrier in a mucositis model induced by irinotecan in mice. Only post-treatment with viable Sc-905 was able to protect mice against the damage caused by chemotherapy, reducing the weight loss, increase of intestinal permeability and jejunal lesions (villous shortening). Besides, this treatment reduced oxidative stress, prevented the decrease of goblet cells and stimulated the replication of cells in the intestinal crypts of mice with experimental mucositis. In conclusion, Sc-905 protects animals against irinotecan-induced mucositis when administered as a post-treatment with viable cells, and this effect seems to be related with the reduction of oxidative stress and preservation of intestinal mucosa.
local.publisher.countryBrasil
local.publisher.departmentENF - DEPARTAMENTO DE NUTRIÇÃO
local.publisher.departmentFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS
local.publisher.departmentICB - DEPARTAMENTO DE MICROBIOLOGIA
local.publisher.departmentICB - DEPARTAMENTO DE PATOLOGIA
local.publisher.initialsUFMG
local.url.externahttps://www.wageningenacademic.com/doi/abs/10.3920/BM2015.0190

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG